Therapeutic advances in gastroenterology · 2025
Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for Helicobacter pylori treatment: a randomized clinical trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jin-Yan, Chen Jin-Hai, Huang Yu-Lin, Li Ji, Xu Dong, Xu Zhong, Lei Xiao-Yi
Аннотация
BACKGROUND: Potassium-competitive acid blockers (P-CABs) have shown potential in Helicobacter pylori (H. pylori) eradication, but the efficacy of dual therapy with P-CABs and amoxicillin remains underexplored.
OBJECTIVES: This study evaluated the efficacy, safety, and compliance of a 14-day vonoprazan-amoxicillin (VA) dual therapy compared to a bismuth-based quadruple therapy (BQT) in treatment-naive patients.
DESIGN: A randomized clinical trial.
METHODS: This single-center, prospective, randomized controlled trial enrolled 250 H. pylori-positive patients from November 2022 to April 2024. Participants were randomly assigned (1:1) to receive 14-day VA dual therapy or BQT (lansoprazole, bismuth, amoxicillin, and clarithromycin). The primary outcomes were eradication rates in intention-to-treat (ITT) and per-protocol (PP) analyses. Secondary outcomes included adverse events and treatment compliance.
RESULTS: Eradication rates in the ITT analysis were 92.0% for the VA dual group and 88.0% for the BQT group (p = 0.292). In the PP analysis, eradication rates were 95.8% and 91.7%, respectively (p = 0.188). The VA dual group demonstrated statistically significant non-inferiority to the BQT group in both the ITT and PP analyses (both p < 0.001). The incidence of adverse events was significantly lower in the VA dual group compared to the BQT group (11.2% vs 20.8%, p = 0.038), with no severe adverse events reported. The compliance rates of both groups were 97.6%.
CONCLUSION: The 14-day VA dual therapy is highly effective and well-tolerated, demonstrating non-inferiority to BQT. Given its reduced antibiotic usage and lower adverse events, it may be a viable first-line alternative for H. pylori in southern China.
TRIAL REGISTRATION: This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2200055752.
OBJECTIVES: This study evaluated the efficacy, safety, and compliance of a 14-day vonoprazan-amoxicillin (VA) dual therapy compared to a bismuth-based quadruple therapy (BQT) in treatment-naive patients.
DESIGN: A randomized clinical trial.
METHODS: This single-center, prospective, randomized controlled trial enrolled 250 H. pylori-positive patients from November 2022 to April 2024. Participants were randomly assigned (1:1) to receive 14-day VA dual therapy or BQT (lansoprazole, bismuth, amoxicillin, and clarithromycin). The primary outcomes were eradication rates in intention-to-treat (ITT) and per-protocol (PP) analyses. Secondary outcomes included adverse events and treatment compliance.
RESULTS: Eradication rates in the ITT analysis were 92.0% for the VA dual group and 88.0% for the BQT group (p = 0.292). In the PP analysis, eradication rates were 95.8% and 91.7%, respectively (p = 0.188). The VA dual group demonstrated statistically significant non-inferiority to the BQT group in both the ITT and PP analyses (both p < 0.001). The incidence of adverse events was significantly lower in the VA dual group compared to the BQT group (11.2% vs 20.8%, p = 0.038), with no severe adverse events reported. The compliance rates of both groups were 97.6%.
CONCLUSION: The 14-day VA dual therapy is highly effective and well-tolerated, demonstrating non-inferiority to BQT. Given its reduced antibiotic usage and lower adverse events, it may be a viable first-line alternative for H. pylori in southern China.
TRIAL REGISTRATION: This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2200055752.